Personalized Medicine: CancerlQ



Marilyn Colgan

Click here to add affiliations

PROBLEM TRYING TO SOLVE

- Approximately 1/3 of our population is at a higher risk of cancer based on their personal and family histories.
- CancerIQ is a tool that helps to:
 - Identify patients who are at an elevated risk of getting cancer.
 - Document if they are interested in talking with a provider trained in genetics to look at whether genetic testing and/or other care plan options can help them reduce their risk of cancer or catch it as early as possible.
 - For interested high risk patients, it sends a more detailed assessment to gather additional information that will determine next steps, which often includes genetic testing.
 - Creates a care plan based on the patient's test results.

OUTCOME/GOALS/IMPACT TO PATIENT

- Results from 2015 through 1/31/25
 - 93,995 unique patients screened
 - 31,066 high risk (33%) genetics eligible
 - 12,217 interested in genetics (39% of eligible)
 - 10,071 patients scheduled for genetics appointment
 - 7,785 genetics appointments completed
 - 7,811 patients with tests entered
 - 7,104 patients with results
 - 912 patients tested positive for 946 mutations
 - 6,854 patients eligible for breast MRI, Tyrer-Cuzick 8 > 20%

JOURNEY TO GET THERE/PLANNED JOURNEY

- 2015: CancerIQ website-based screening offered at Peoria mammography sites
- 2016-2017: Expanded to Rockford mammography sites
- 2022-2023: Expanded to Peoria GI, Bloomington/Pontiac mammography sites
- 2023: CancerIQ app integrated into Epic (OSF is one of CancerIQ's first customers to integrate and implement this). Peoria mammography, Peoria GI, and the Bloomington/Pontiac mammography sites were upgraded to the new version of the tool. LCMMC breast surgeon office mammography sites were implemented using the new version
- 2025: Epic/CancerIQ integration upgrade for Rockford mammography sites
- Next Steps:
 - 2 more mammography sites are interested in implementing CancerIQ
 - Charter approved to look at enhancements to the genetic cancer risk assessment process and storage of test results

DIRECT IMPACT TO PATIENT/FAMILIES

- Mary's Story:
 - After completing the CancerIQ screening at the OSF Center for Breast Health, Mary was identified as high-risk based on her personal and family health history.
 - Mary met with an APP geneticist to talk about her risk and genetic testing options.
 - Genetic testing revealed ATM and CHEK2 genetic variants.
 - A care plan was created with suggested exams, testing and a referral to a breast surgeon.
 - A recommended bilateral MRI six months post-mammogram found bilateral suspicious enhancing lesions. Biopsies were recommended.
 - The biopsy found a stage 0 ductal carcinoma in situ in one breast and a high-risk lesion in the other.
 - A new care plan was developed, including:
 - Bilateral mastectomies and reconstruction
 - No additional treatment needed
 - Continued surveillance for other cancers
- Early identification of Mary's high risk and access to additional testing helped detect her cancer at the earliest stage, likely saving her life.

